Completed PHASE2 INTERVENTIONAL 1-arm NCT01194271

Neoadjuvant Ipilimumab in Prostate Cancer

A Neoadjuvant Phase IIa Study of Ipilimumab {Formerly Known as MDX-010 (BMS-734016)} Plus Hormone Ablation in Men With Prostate Cancer Followed by Radical Prostatectomy.

Sponsor: Bristol-Myers Squibb

Conditions Prostate Cancer

Interventions Ipilimumab Leuprolide Acetate Radical Prostatectomy

Updated 9 times since 2017 Last updated: May 22, 2024 Started: Sep 30, 2010 Primary completion: Oct 31, 2015 Completion: Oct 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Prostate Cancer, this trial is completed. The trial is conducted by Bristol-Myers Squibb and has accumulated 9 data snapshots since 2010. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Oct 2023 — Jul 2024 [monthly]

Completed PHASE2
Apr 2023 — Oct 2023 [monthly]

Completed PHASE2
Jan 2021 — Apr 2023 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Oct 2020 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Oct 2020 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Sep 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bristol-Myers Squibb
M.D. Anderson Cancer Center

Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States